In this issue of Blood, Green et al identified an innovative and promising pretargeted radioimmunotherapy (RIT) approach for the treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma. Pretargeted RIT of B-cell malignancies with a CD38 bispecific monoclonal antibody (mAb) is a novel approach, and the results achieved in preclinical models are very impressive. CD38 is an excellent target because it has high density and stable expression in multiple myeloma and NHL.(1)
No takes yet. Share an insight, caveat, or question.
Donald J. Buchsbaum (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: